Lecanemab-irmb bulk supplier for pharma manufacturers

Lecanemab-Irmb 100 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 100 mg/mL

Reference Brands: Leqembi (USA/EU)

Category: Neurology

Lecanemab-irmb is a humanized monoclonal antibody used for early Alzheimer’s disease. It targets and clears amyloid-beta protofibrils to help slow cognitive and functional decline. The treatment is administered under medical supervision as part of a disease-modifying therapy program for patients with mild cognitive impairment or mild dementia due to Alzheimer’s.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Lecanemab-Irmb? List it or send an offer →

Product Description:

Lecanemab is a humanised monoclonal antibody that binds soluble amyloid-beta protofibrils, the aggregated species thought to be most toxic to synapses, as well as plaque. In early Alzheimer's disease with confirmed amyloid pathology it slowed clinical decline by about a quarter over eighteen months. The effect is real but modest, and it depends on starting treatment early, at the mild cognitive impairment or mild dementia stage.

It is given as an intravenous infusion every two weeks; a subcutaneous autoinjector for maintenance dosing has since been approved in the US. The central risk is amyloid-related imaging abnormalities — cerebral oedema and microhaemorrhage — mostly asymptomatic but occasionally serious or fatal. Risk is highest in APOE ε4 homozygotes, so genotyping is part of eligibility, and MRI monitoring is scheduled before and during the early doses. Anticoagulant use raises concern about intracerebral haemorrhage.

Sourcing notes. Originator biologic, on patent, no biosimilar. Authorised in the US and — after re-examination — in the EU in 2025, where use is restricted to patients who are not APOE ε4 homozygotes. Use requires amyloid PET or CSF biomarker confirmation, genotyping and repeated MRI, which limits realistic demand to markets with that infrastructure. Supply is through authorised distribution or named-patient routes, with cold chain throughout.

How Lecanemab-Irmb is supplied today, and licensing ahead of patent expiry

Lecanemab-Irmb is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Lecanemab-Irmb, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Lecanemab-Irmb supply →

Back to Listing

Frequently Asked Questions

Lecanemab-irmb is used for treating early Alzheimer’s disease, specifically in patients with mild cognitive impairment or mild dementia who have confirmed amyloid-beta buildup in the brain.

It is a humanized IgG1 monoclonal antibody developed to target aggregated forms of amyloid-beta (Aβ) in the brain.

The trade name is Leqembi.

It is developed and marketed by Eisai in partnership with Biogen.

The generic name is Lecanemab-irmb.

The brand name is Leqembi.

It is manufactured by Eisai facilities under global production and quality standards.

Leqembi (Lecanemab) is developed and sold by Eisai and Biogen. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.